STAT+: Roche ends Huntington’s gene-silencing programs

STAT PlusNewsletterThe Readout Roche ends Huntington’s gene-silencing programs ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana Keshavan and John WilkersonJuly 10, 2026 Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter.John Wilkerson[email protected]John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic. Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to promote Medicare’s new obesity drug discount program.Advertisement I got coffee with my cousin this morning here in SF. Before leaving for his job at an AI behemoth, he said the bone-chilling July gloom is perfect “working weather.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 9, 2026 STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Advertisement Adam's Biotech Scorecard July 9, 2026 STAT Plus: 931 days. The drug approval scandal hiding in plain sight Biotech July 9, 2026 STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug Special Report July 9, 2026 STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere Subscriber Picks